In vitro analysis of new putative biomarkers for OCT2/MATE-mediated renal drug-drug interactions

被引：0
|
作者：
Picurova, J. [1 ]
Mueller, F. [1 ,2 ]
Koenig, J. [1 ]
Stopfer, P. [1 ]
Fromm, M. F. [1 ]
Gessner, A. [1 ]
机构：
[1] Friedrich Alexander Univ Erlangen Numberg, Inst Expt & Clin Pharmacol & Toxicol, Erlangen, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2024年 / 397卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P075
引用
收藏
页码：S35 / S36
页数：2
相关论文
共 50 条
  • [41] Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin
    Liu, Yanqing
    Zheng, Xiaoli
    Yu, Qinqin
    Wang, Hua
    Tan, Fuqing
    Zhu, Qianying
    Yuan, Lingmin
    Jiang, Huidi
    Yu, Lushan
    Zeng, Su
    SCIENCE TRANSLATIONAL MEDICINE, 2016, 8 (348)
  • [42] Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine
    Mueller, Fabian
    Koenig, Joerg
    Hoier, Eva
    Mandery, Kathrin
    Fromm, Martin F.
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (06) : 808 - 815
  • [43] Analysis of the mechanism of drug-drug interactions involving transporter-mediated hepatic uptake
    Shitara, Y
    Hirano, M
    Sato, H
    Sugiyama, Y
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2004, 124 : 37 - 41
  • [44] USE OF A RENAL OCT2/MATE BIOMARKER (N1-METHYLNICOTINAMIDE) TO ENABLE THE EARLY CLINICAL ASSESSMENT OF METFORMIN DRUG INTERACTION POTENTIAL
    Mathialagan, Sumathy
    Rodrigues, A. David
    DRUG METABOLISM AND PHARMACOKINETICS, 2024, 55
  • [45] Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
    Safar, Zsolt
    Vasko, Balazs
    Ritchie, Tasha K.
    Imre, Gabor
    Mogyorosi, Karoly
    Erdo, Franciska
    Rajnai, Zsuzsanna
    Fekete, Zsolt
    Szeremy, Peter
    Muka, Laszlo
    Zolnerciks, Joseph K.
    Heredi-Szabo, Krisztina
    Ragueneau-Majlessi, Isabelle
    Krajcsi, Peter
    CURRENT DRUG METABOLISM, 2016, 17 (05) : 430 - 455
  • [46] Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling
    Posada, Maria M.
    Bacon, James A.
    Schneck, Karen B.
    Tirona, Rommel G.
    Kim, Richard B.
    Higgins, J. William
    Pak, Y. Anne
    Hall, Stephen D.
    Hillgren, Kathleen M.
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (03) : 325 - 334
  • [47] STUDY TO ASSESS THE FOOD EFFECT ON PLASMA LEVELS OF EMERGING ENDOGENOUS BIOMARKERS OF TRANSPORTER MEDIATED DRUG-DRUG INTERACTIONS
    King-Ahmad, Amanda
    Rago, Brian
    Luo, Lina
    Rodrigues, A. David
    Ramanathan, Ragu
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S92 - S92
  • [48] Comment on "Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin"
    Winter, Stefan
    Fisel, Pascale
    Buettner, Florian
    Nies, Anne T.
    Stenzl, Arnulf
    Bedke, Jens
    Schwab, Matthias
    Schaeffeler, Elke
    SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (391)
  • [49] STATISTICAL ANALYSIS TO COMPARE VARIOUS IN VITRO CRITERIA FOR PREDICTING P-GLYCOPROTEIN TRANSPORTER MEDIATED DRUG-DRUG INTERACTIONS IN VIVO
    Arya, V.
    Zhou, T.
    Yang, X.
    Vaidyanathan, J.
    Zhang, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S21 - S21
  • [50] A drug-drug interaction study to evaluate the impact of peficitinib on OCT1-and MATE1-mediated transport of metformin in healthy volunteers
    Shibata, Mai
    Toyoshima, Junko
    Kaneko, Yuichiro
    Oda, Kazuo
    Nishimura, Tetsuya
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (08) : 1135 - 1141
12345